StreetAlpha.app
Home › Stocks › ORKA

Oruka Therapeutics, Inc. (ORKA)

Healthcare
$96.32
▼ −2.94%
LAST CLOSE · NOV 17

Oruka Therapeutics develops antibody treatments for psoriasis and other immune and inflammatory conditions. It last closed at $96.32 on Nov 17, down 2.94% on the day. The average 12-month price target from 2 analysts is $182.50 (+89.5% from the last close), with a high of $200.00 and a low of $165.00. Over the past 90 days StreetAlpha recorded 1 whale options trade in ORKA, 100% of them bullish and 0% bearish. In the past 30 days there were 2 dark pool prints totaling $2.2M, the largest $1.1M.

AI Auto Pilots
Is ORKA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$152.6M
Free cash flow
−$123.9M
Valuation
Market cap
$6.5B
67.8M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$191.5M
At Sep 30
Shareholder equity
$1.2B
Shares outstanding
67.8M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2020: −$9.7M−$9.7MFY2020FY2021: −$19.3M−$19.3MFY2021FY2022: −$9.9M−$9.9MFY2022FY2023: −$5.3M−$5.3MFY2023FY2025: −$105.4M−$105.4MFY2025

From ORKA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated ORKA in the past 90 days, not enough for a consensus
Average 12-month target
$182.50
▲ 89.5% upside

Based on 2 analysts who set a price target on ORKA in the past 90 days. The average target is $182.50, with a high of $200.00 and a low of $165.00, compared with the last close of $96.32.

Low $165.00Avg $182.50High $200.00
Blue marker: last close $96.32
Highest target$200.00
Average target$182.50
Lowest target$165.00
Latest rating changes
GuggenheimReiterated
Oct 27Buy$200
WedbushReiterated
Oct 27Buy$165
GuggenheimReiterated
Aug 11Buy$200
WedbushReiterated
Aug 11Buy$165
HC Wainwright & Co.Reiterated
Aug 3Buy$120
DateFirmActionRatingPrice target
Oct 27GuggenheimReiteratedBuy$200
Oct 27WedbushReiteratedBuy$165
Aug 11GuggenheimReiteratedBuy$200
Aug 11WedbushReiteratedBuy$165
Aug 3HC Wainwright & Co.ReiteratedBuy$120
Loading…

Technical Analysis

ORKA · as of the Nov 17 close · updated after every close
Uptrend

The stock sits between its 20 and 50 day averages. It is 24% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 51). The nearest support is the swing low (Aug 10) at $95.50, and the nearest resistance the swing high (Sep 8) at $96.44.

Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 6.1%/day
Key levels
$115.5252 week high+19.9%
$99.71Pivot R1+3.5%
$97.38Pivot+1.1%
$96.9620 day average+0.7%
$96.44Swing high (Sep 8)+0.1%
$96.32Last close
$95.50Swing low (Aug 10)−0.9%
$93.99Pivot S1−2.4%
$92.64100 day average−3.8%
$89.8550 day average−6.7%
$73.29200 day average−23.9%
$25.2352 week low−73.8%
Indicators
RSI (14)50.91Middle of its rangeNeutral
MACD4.35Below its signal lineBearish
Stochastic35.4Middle of its rangeNeutral
ADX (14)32.5Trending up
Williams %R-88.2Oversold below −80, overbought above −20Oversold
CCI (20)5.7Oversold below −100, overbought above 100Neutral
Rate of change−3.2%Change over 10 sessionsBearish
ATR (14)$5.85Typical daily range, 6.1% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for ORKA

What happened before

See how ORKA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ORKA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ORKA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Nov 3 – Nov 3
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$2.2M
Largest print
$1.1M
Loading…

ORKA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲156 buying vs 113 selling
  • ▲Held by funds +3.8 pts
  • ●Funds holding +2
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding259257+0.8%
In funds' top 10714−50.0%
Held by funds113.2%109.3%+3.8 pts
New / increased38 / 11896 / 94−17.9%
Reduced / sold out77 / 3647 / 27+52.7%
Put/call ratio1.461.00+45.9%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ORKA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ORKA is in one of them and how their past ORKA trades turned out.

ORKA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ORKA in an article yet. Here's the latest on the wider market.

About Oruka Therapeutics

Oruka Therapeutics is a biopharmaceutical company based in Menlo Park, California. It is developing antibody treatments for psoriasis, a chronic skin disease, along with other immune and inflammatory conditions such as hidradenitis suppurativa and psoriatic arthritis. Its lead candidates are designed to act on IL-23 and IL-17 signaling. The company's products are still in clinical trials and not yet approved, and it aims to serve people living with these chronic skin and joint conditions.

Headquarters
Menlo Park, CA